- Molecular NameLamivudine
- SynonymLamivudine [Usan:Ban:Inn]
- Weight231.276
- Drugbank_IDDB00709
- ACS_NO134678-17-4
- Show 2D model
- LogP (experiment)-0.93
- LogP (predicted, AB/LogP v2.0)-1.11
- pka4.3
- LogD (pH=7, predicted)-1.11
- Solubility (experiment)70 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-0.71
- LogSw (predicted, AB/LogsW2.0)31.69
- Sw (mg/ml) (predicted, ACD/Labs)44.58
- No.of HBond Donors3
- No.of HBond Acceptors6
- No.of Rotatable Bonds2
- TPSA113.45
- StatusFDA approved
- AdministrationN/A
- PharmacologyA potent nucleoside analog reverse transcriptase inhibitor (nRTI).
- Absorption_value86.0
- Absorption (description)In healthy volunteers lamivudine is rapidly absorbed following an oral administration, reaching peak plasma concentrations within 1 to 1.5 h.
- Caco_2N/A
- Bioavailability86.0
- Protein binding36.0
- Volume of distribution (VD)1.30 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmBetween 5 and 10% undergoes hepatic metabolism to form a trans-sulfoxide metabolite.
- Half life9.11 h
- ExcretionRenal (circa 70%)
- Urinary Excretion49~85
- Clerance4.95 ml/min/kg
- ToxicitySelected clinical adverse events with a ≥5% frequency are listed below. Body as a whole: Headache; Malaise & fatigue; Fever or chills. Digestive: Diarrhea; Nausea & vomiting; Anorexia and/or decreased appetite; Abdominal pain; Abdominal cramps; Dyspepsia. Nervous System: Neuropathy; Insomnia & other sleep disorders; Dizziness; Depressive disorders. Respiratory: Nasal signs & symptoms; Cough. Skin: Skin rashes. Musculoskeletal: Musculoskeletal pain; Myalgia; Arthralgia.
- LD50 (rat)N/A
- LD50 (mouse)N/A